Novocure

Congratulations to the 23 Novocure runners from our team in Germany for successfully completing the “B2Run 2025” race in Munich! And a big thank you to all the colleagues who cheered for them along the 5.7km (3.5 mile) route. This event was a great opportunity to spend time with colleagues outside of the office. #WeAreNovocure #B2RunMunich To learn more about Novocure or join our team, visit our careers page: https://lnkd.in/eVZKr7r

Today is Glioblastoma Awareness Day. At Novocure, we are committed to advancing the treatment and research of #glioblastoma, one of the most aggressive forms of brain cancer. We are proud to support the National Brain Tumor Society for their leadership of the #GBMAwarenessDay initiative. #GBMDay #BTAM #GBMAwarenessDay

#PancreaticCancer Update from the ESMO Gastrointestinal (GI) Cancers Congress 2025: The final secondary endpoint results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer were presented today as an oral presentation at ESMO GI. Learn more in our press release: https://lnkd.in/d_JnZpen

Novocure will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025. Read more in our press release: https://lnkd.in/d_JnZpen #ESMOGI25 #PancreaticCancer

Novocure will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Read more in our press release: https://lnkd.in/dJ-BMpbB

Many cancers can spread from their original site into other regions of the human body. These relocated cancer deposits called metastases can affect important parts of the body’s nervous system such as the brain and cerebrospinal fluid. Lung cancer is the leading source of brain metastasis in men, and breast cancer is the leading source for brain metastasis in women.   June is Brain and Spine Metastasis Awareness Month. We are proud to support the Metastatic Brain Tumor Collaborative, created by the American Brain Tumor Association to inform, support and empower people facing this diagnosis. Learn more about metastatic brain tumors here: https://lnkd.in/gdsy7mki   #BrainMetastases #MetastaticBrainCancer #MetsGetAwareness

Results from the 2-THE-TOP trial led by David D. Tran, MD, PhD, Chief, Division of Neuro-Oncology, Department of Neurosurgery, Co-Director, University of Southern California (USC) Brain Tumor Center Keck Medicine of USC, were published by the Cell Press journal, 𝘔𝘦𝘥. The 2-THE-TOP trial, “The publication, Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma (2-THE-TOP): A Phase 2 study,” assessed the efficacy and safety of TTFields therapy when used with pembrolizumab and temozolomide to treat newly diagnosed glioblastoma (GBM). This publication provides additional characterization of the immunogenic effects observed with TTFields therapy. https://lnkd.in/edSQNpsu

At Novocure we are working to improve the future of cancer care by advancing our innovative therapy, Tumor Treating Fields to treat more solid tumor cancers. Our CEO Ashley Cordova shares her perspective as part of the “The Future of Cancer Care” expert roundtable. https://lnkd.in/ent6hbsz

June 8 is World Brain Tumor Day, a day founded to honor brain tumor patients and their families. At Novocure, we would like to recognize those affected by brain tumors, the community working to provide care and advocacy as well as those advancing research of treatments for brain cancers. #WorldBrainTumorDay #braintumor #braincancer #PatientForward

We are proud to have been named a Top Donor to Conquer Cancer, the ASCO Foundation, with a mission to enable acceleration of breakthroughs in lifesaving research and empower people everywhere to conquer cancer. This mission resonates closely with our own patient-forward mission of working to extend survival in some of the most aggressive forms of cancer. On May 31, our CEO Ashley Cordova accepted the award during the 2025 ASCO Annual Meeting.